The bone disease in multiple myeloma is caused by an uncoupling of bone formation from bone resorption. A key difference between patients with -and patients without osteolytic lesion is that the latter have fewer and less active osteoblasts. HGF is often produced by myeloma cells and is found at high supported by the observation of a negative correlation between HGF and a marker of osteoblast activity, bone specific alkaline phosphatase (rho=-0,45, p=0,008), in sera from 34 myeloma patients. These observations suggest that HGF inhibits bone formation in multiple myeloma.
Introduction
Almost all patients with multiple myeloma develop osteolytic lesions and/or diffuse osteopenia. The presence of myeloma cells in the bone marrow leads to both increased number and increased activity of osteoclasts as well as reduced number and dysfunction of osteoblasts 1, 2 . During the early stages of the disease, enhanced osteoclast activation is, at least partly, compensated by an increase in bone formation. As the disease progresses, the osteoblasts are fewer and less active, so that bone resorption is uncoupled from bone formation 3 . Recently, several factors have been proposed to be involved in the dysregulation of osteoblastogenesis in multiple myeloma [4] [5] [6] [7] . However, the mechanisms for reduced bone formation in myeloma patients are still not completely understood.
We have shown that myeloma cells produce hepatocyte growth factor (HGF) 8 . Others have shown that HGF is among the most upregulated genes in myeloma cells as compared to normal plasma cells 9 . High serum concentration of HGF is associated with poor prognosis in myeloma patients 10 , and HGF has been shown to play several roles in disease progression To adjust for differences in PCR efficiency, relative standard curves were obtained from five-fold dilutions of pooled cDNA (corresponding to 40 ng RNA to 32 pg RNA) from BMP-2 treated C2C12 cells for both target and reference genes. Then calibrator-normalized relative quantification with efficiency correction was carried out with Real Quant Software (Roche Applied Science). Samples were run in triplicates. The ratio of target mRNA/GAPDH was in control samples set to 1.
Western Blot
Nuclear extracts were prepared using Nuclear Extract Kit (Active Motif)
according to the manufacturer's instructions. 30-100 ug protein were loaded onto precasted 10-12% Bis-Tris Gels (Invitrogen) and subjected to SDS-PAGE. Gels were then blotted onto nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk in 0,1% Tween-20-Tris Buffered Saline 
Immunofluorescence microscopy
C2C12 cells were serum-starved for 24 hours before treatment with BMP-2 (300 ng/ml) and/or HGF (100 ng/ml) for 45 minutes. Then the cells were fixed on ice with 3% para-formaldehyde in PBS for ten min. Subsequently, the cells were blocked and permeabilized with 2,5%BSA/20%A+serum/0,2% saponin in PBS (blocking/permeabilization buffer) for 20 min. Anti-phospho Smad-1,-5,-8 (Cell Signaling) were diluted 1:100 in blocking buffer and incubated for one hour. After three washes in blocking buffer, Alexa -633-conjugated goat anti-rabbit (Molecular Probes) was added and cells incubated for 45 min. The cells were subsequently washed twice before examination by confocal microscopy (LSM 510; Zeizz, Jena, Germany). Unless otherwise stated, the procedure was performed at room temperature. Cells which had fluorescence intensity in the nucleus higher than a certain threshold (100 pixels) were counted as positive for phospho-Smad1,5,8 nuclear translocation. without BMP-2 (300 ng/ml) or HGF (100 ng/ml). Then media were removed, the cells washed with PBS, and 20 ul 1X cell culture lysis reagent (Promega) were added to lyse the cells. 70 ul luciferase assay substrate (Promega) were added to 15 ul of the lysates, and luciferase activity was measured using a luminometer (Viktor 1420, Perkin Elmer). By transfecting hMSC with pMaxGFP (Amaxa Biosystems) the transfection efficiency was determined to be 40-50%.
Transfection and reporter-assay

Patients
Sera from 34 patients with newly diagnosed multiple myeloma were analyzed in the in vivo part of the study. All patients had symptomatic disease and an expected distribution of myeloma subtypes: 25 patients had IgG subtype, 5 patients IgA, 3 patients light chain disease, and 1 patient non-secretory disease. All but 2 patients had lytic bone disease and/or pathological fractures. Sera were taken before start of treatment and stored at -80°C until analysis. The study was approved by the local ethics committee at Aarhus University Hospital. Informed consent was provided according to the Declaration of Helsinki. Patient characteristics have been described in more details elsewhere 20 .
Serum assays
HGF in serum was measured by enzyme linked immunosorbent assay (ELISA) according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Markers of bone formation
Total alkaline phosphatase activity in serum was measured spectrophotometrically using p-nitrophenylphosphate as a substrate, and the bone-specific alkaline phosphatase (bALP) was determined by lectin 
Markers of bone resorption
Serum concentration of C-terminal telopeptide of collagen type I was analyzed by two different assays, the ICTP RIA assay from Farmos Diagnostica (Oulunsalo, Finland), which uses rabbit polyclonal antibodies for detection of a cross-linked fragment liberated by metalloproteinase activity 25, 26 , and the Ctx- 
Statistics
Statistical analyses were performed with SPSSX/PC computer program (SPSS, Chicago, IL). Results were considered statistically significant when p<0.05. Skewed variables (Kurtosis >7) were transformed by the natural logarithm (ln) before entering analyses requiring normal distribution.
RESULTS
HGF inhibits osteoblast differentiation in vitro
We 
HGF inhibits the expression of osteoblast-specific transcription factors Runx2 and Osterix
Osteoblast differentiation is regulated by sequential expression of the osteoblast-specific transcription factors Runx2 and Osterix [32] [33] [34] [35] . In C2C12 cells, Runx2 mRNA was expressed at high levels after four days of BMP-2 treatment, and furthermore, although still present, the expression decreased after another two days of culturing ( Figure 3A) . Osterix, on the other hand, was induced later in the differentiation process and showed high expression after six days of BMP-2 treatment ( Figure 3B ). HGF inhibited the BMP-2-induced expression of both Runx2 and Osterix mRNA ( Figure 3A-B) . The decrease of BMP-2-induced Runx2 mRNA in C2C12 cells in the presence of HGF resulted in a decrease of Runx2 protein expression as shown in Figure   3C . hMSC cultured in osteogenic media showed a basal Runx2 protein expression ( Figure 3D ). BMP-2 treatment enhanced this basal expression, and more importantly, HGF inhibited the BMP-induced Runx2 protein expression also in hMSC ( Figure 3D ). In conclusion, HGF inhibits the BMP-2-induced expression of the osteoblast specific transcription factors Runx2 and Osterix.
HGF promotes proliferation of human mesenchymal stem cells
When mesenchymal stem cells differentiate, proliferation is inhibited 31 . In line with this, we found that BMP-2 inhibited the proliferation of hMSC ( Figure 4 ).
Moreover, although HGF alone had no effect on the expression of osteoblast markers ( Figure 1 and 2), we found that HGF treatment promoted proliferation of hMSC as compared to both untreated and BMP-2-stimulated cells ( Figure   4 ). Furthermore, HGF abolished the anti-proliferative effect of BMP-2 ( Figure   4 ), indicating that HGF keeps the cells in a proliferative, undifferentiated state.
The influence on proliferation was most pronounced during the first two days after osteogenic induction, after seven days, there was no significant difference in proliferation rates (data not shown). In contrast, neither BMP-2 nor HGF had any significant influence on proliferation of C2C12 cells (data not shown).
HGF inhibits BMP-2-signaling
The osteogenic activity of BMPs is partly mediated by nuclear translocation of 
HGF correlates negatively with markers of osteoblast activity in patients with multiple myeloma
Since we found that HGF inhibited osteoblastogenesis in vitro, we wanted to investigate whether serum concentrations of HGF correlate with markers of osteoblast activity in myeloma patients. We found that HGF correlated significantly to bone specific alkaline phosphatase (bALP) in a Spearman rank correlation analysis (r= -0,45, p=0,008) ( 49 . We did not find any significant correlations of HGF to osteoclast markers in our analyses. However, the number of patient samples available in this study was relatively small, which may explain our inability to find the significant correlations reported earlier. Together with Smad 4, the phosphorylated R-Smads translocate to the nucleus where they associate with other proteins to regulate transcription 36 .
We found that HGF inhibited Smad signaling both in hMSC and C2C12 cells, suggesting that the effect of HGF on BMP-induced osteoblastogenesis may . Therefore, at this point, we cannot exclude the possibility that HGF acts on other pathways in addition to the Smad pathway in the regulation of osteoblast differentiation.
The influence of growth factors on osteoblast differentiation is reported in several papers, although different mechanisms and even opposing effects of the same factors have been described [60] [61] [62] [63] [64] [65] [66] . It may be that transient exposure to mitotic growth factors such as FGF, EGF and PDGF enhance osteogenesis, whereas continuous exposure inhibits osteoblast differentiation.
The enhanced osteogenesis could be due to an increased self-renewal of mesenchymal stem cells that leads to an increase in number of cells that can become fully mature osteoblasts when osteogenic stimuli are present. HGF has by others been shown to stimulate the expression of early osteoblast markers (ALP activity) in preosteoblasts 67 , and has also been reported to stimulate 1, 25-dihydroxyvitamin D 3 -induced osteoblast differentiation by increased proliferation of osteoblast precursors 68 . In line with the latter study, we observed a proliferative effect of HGF on hMSC. However, in contrast, HGF on its own had no effect on the differentiation towards osteoblasts, and, importantly, inhibited BMP-2-induced osteoblastogenesis. We propose that HGF is found at high concentrations in the bone marrow of myeloma patients.
We have previously shown that about 50% of the patients with multiple myeloma have elevated levels of HGF in bone marrow plasma when compared to healthy persons. In some of the patients the concentration of HGF in bone marrow plasma was extremely high, exceeding 100 ng/ml 17 .
The differentiation of mesenchymal stem cells and osteoblast precursors in many myeloma patients thus occurs in an environment containing abnormal levels of this cytokine. The in vitro and in vivo data presented in this study suggest that HGF reduce bone formation rates in myeloma patients and hereby may contribute to the development of myeloma bone disease.
Consequently, inhibition of HGF signaling could be useful in the treatment of the bone disease in multiple myeloma. were 300 ng/ml BMP-2 and 100 ng/ml HGF. 
